Splash Beverage Acquires Global Rights to CannEpil Therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
FORT LAUDERDALE, Fla., July 7, 2026 Splash Beverage Group, Inc. has announced the acquisition of exclusive global licensing rights...
NEW YORK, July 7, 2026 The American Parkinson Disease Association (APDA) has announced the launch of “Bridging Mental Health...
MISSISSAUGA, Ontario, Feb. 19, 2026 — Covalon Technologies Ltd. announced a strategic educational collaboration with the Association for Vascular...
